ライフサイエンスコーパス: post-mortem brain

1 o define the tau PTM landscape present in AD post-mortem brain.

2 in protein changes similar to schizophrenia post-mortem brain.

3 mation, demyelination and remyelination from post-mortem brains.

4 required to form the aggregates observed in post-mortem brains.

5 hesis has gained indirect support from human post-mortem brain analyses and genetic studies, little i

6 Post-mortem brain analyses and some genetic studies have

7 Six patients had post-mortem brain analysis available for assessment of n

8 been informed by both direct analysis of the post-mortem brain and by study of the biological consequ

9 pes predicted levels of NPY messenger RNA in post-mortem brain and lymphoblasts, and levels of plasma

10 the cohort (21 familial, 137 sporadic) were post-mortem brain and spinal cord donors.

11 Post-mortem brain and spinal cord tissue has been examin

12 and TRIM33 in the human prefrontal cortex of post-mortem brains between subjects with and those witho

13 AD using samples from four independent human post-mortem brain cohorts.

14 In a series of patients with post-mortem brain examination, imaging using [(123)I]iof

15 d no reliable method of diagnosis other than post-mortem brain examination.

16 Two patients underwent post-mortem brain examination.

17 Additionally, post-mortem brain extracts from patients with Alzheimer

18 ines and demonstrate its upregulation in the post-mortem brain from 15q11-13 duplication patients for

19 d protein are reduced in multiple regions of post-mortem brain from patients diagnosed with schizophr

20 mately 50% in various cortical structures of post-mortem brain from patients diagnosed with schizophr

21 ation of GFAP and AQP4 immunoreactivities in post-mortem brains from adult baboons with cerebral hypo

22 Studies of post-mortem brains from Alzheimer disease patients sugge

23 prefrontal cortex in an extensive series of post-mortem brains from fetal development through ageing

24 motor cortex, hippocampus and cerebellum of post-mortem brains from HD individuals, particularly in

25 ide microRNA (miRNA) expression profiling in post-mortem brains from individuals with ASD and control

26 scovery and proteomics approach by comparing post-mortem brain material from schizophrenia patients a

27 Here we present evidence from post-mortem brain (N = 21 patients, compared with 17 pre

28 r from an independent (Oxford, UK) cohort of post-mortem brains (n = 74), we confirmed the significan

29 We analysed post-mortem brains obtained from a cohort of 85 subjects

30 estigated large-scale gene expression in the post-mortem brain of MDD subjects paired with matched co

31 le of the immune system in a large sample of post-mortem brain of patients with schizophrenia: RNA se

32 VDAC1 is overexpressed in post-mortem brains of Alzheimer disease (AD) patients.

33 cortical, limbic and subcortical areas, from post-mortem brains of familial Alzheimer's disease (n =

34 Alcohol-dependent rats as well as post-mortem brains of human alcoholics and controls were

35 ast growth factor (FGF) system is altered in post-mortem brains of individuals with major depressive

36 Altered DISC1 expression in the post-mortem brains of individuals with psychiatric illne

37 gomers in brain lysates prepared from frozen post-mortem brains of normal, Alzheimer's disease and DL

38 L), enhanced production of which is found in post-mortem brains of Parkinson disease patients.

39 clein mRNA and soluble protein in five human post-mortem brain regions from four groups of individual

40 ) to measure metabolites and metals in seven post-mortem brain regions of nine AD patients and nine c

41 ression Consortium involving 12 human frozen post-mortem brain regions.

42 Analysis of three independent data sets of post-mortem brains revealed signs of increased methylati

43 ay approach for gene expression profiling in post mortem brain samples from patients with cirrhosis w

44 We analyzed MSUT2 protein in age-matched post-mortem brain samples from AD patients and observe a

45 ripotent stem cell-derived motor neurons and post-mortem brain samples from ALS patients.

46 compared DSCR1 (Adapt78) mRNA expression in post-mortem brain samples from Alzheimer's disease patie

47 In comparison, post-mortem brain samples from Down syndrome patients (w

48 ed these to a series of fibroblast lines and post-mortem brain samples from individuals with either a

49 tant HTT and its oligomeric intermediates in post-mortem brain samples from patients with Huntington'

50 APT H1/H2 haplotypes on tau transcription in post-mortem brain samples from patients with Lewy body d

51 pression of chosen nuclear import factors in post-mortem brain samples from patients with TDP-43 posi

52 We used it to examine post-mortem brain samples from seven subjects who had ha

53 hrenia and bipolar disorder by analyzing 115 post-mortem brain samples from the frontal lobe.

54 omplexes of Abeta and COX-2 were detected in post-mortem brain samples in greater amounts in AD tissu

55 nular osmiophilic material in skin biopsy or post-mortem brain samples of affected members in the Swe

56 e-wide DNA methylation was quantified in 262 post-mortem brain samples, representing tissue from four

57 to examine mRNA expression of parvalbumin on post-mortem brain sections.

58 In HD post-mortem brain, specific antibody reagents detect eac

59 Examination of post-mortem brain specimens revealed significant levels

60 Neuroimaging, in vitro and post-mortem brain studies were consistent with an elevat

61 measures of correlated gene expression in a post mortem brain tissue data set.

62 iNOS) to be prevalent in the plaque areas of post mortem brain tissue from patients with MS.

63 oups, though, as with any method for imaging post mortem brain tissue, care should be taken when inte

64 Post-mortem brain tissue (12 multiple sclerosis and eigh

65 A series of post-mortem brain tissue and in vitro experiments sugges

66 ble protein aggregates in vitro and in human post-mortem brain tissue but the cellular dynamics of th

67 Neuropathological analysis of post-mortem brain tissue demonstrated that pIRE1alpha is

68 mmunohistochemical analysis was performed on post-mortem brain tissue from 26 cases with primary prog

69 at function in sound source localization, in post-mortem brain tissue from autistic individuals.

70 f alpha-synuclein with PSEN1 was detected in post-mortem brain tissue from cognitively normal cases a

71 In a blinded study with post-mortem brain tissue from patients with Parkinson's

72 istant aggregates, which are also present in post-mortem brain tissue from patients.

73 We examined post-mortem brain tissue from six patients with lacunar

74 Tof-MS) and chemometrics for the analysis of post-mortem brain tissue from subjects with Alzheimer's

75 and 14 H1/H2 heterozygous control individual post-mortem brain tissue from two brain regions.

76 We have compared KLK6 expression in post-mortem brain tissue in AD, vascular dementia (VaD)

77 ies revealed increased levels of sortilin in post-mortem brain tissue of AD patients and that overexp

78 ongitudinal retrospective study, we analysed post-mortem brain tissue of all individuals with an Alzh

79 More TGF-beta1 messenger RNA was present in post-mortem brain tissue of Alzheimer's patients than in

80 fficient purification of inclusions from the post-mortem brain tissue of FXTAS patients.

81 ans and ruminants relies on the detection in post-mortem brain tissue of the protease-resistant form

82 Moreover, post-mortem brain tissue studies showed increases in who

83 ously been employed to biochemically profile post-mortem brain tissue, and the novel methods describe

84 In both tissue culture and post-mortem brain tissue, we show that the MAPT H1 haplo

85 In post-mortem brain tissue, we show that the total level o

86 mble changes observed in human schizophrenia post mortem brain tissues.

87 we conducted whole transcriptome analysis of post-mortem brain tissues (cingulate cortex) from SCZ, B

88 In post-mortem brain tissues from AIDS patients with opport

89 Post-mortem brain tissues from post-stroke dementia and

90 parate neuronal and glial DNA fractions from post-mortem brain tissues.

91 distribution of neurofibrillary pathology in post-mortem brains was used to classify SPET scans taken